Clovis Rubraca Improves Progression-Free Survival in Advanced Ovarian Cancer

 

• Subgroup analysis from the Phase 3 ATHENA trial evaluating Rubraca monotherapy versus placebo (ATHENA-MONO) presented in a Mini Oral session at the ESMO Congress 2022
• Results reinforce potential of Rubraca as a first-line maintenance treatment option in a broad population of patients with ovarian cancer irrespective of molecular characteristics, with or without high risk factors for progression

https://www.marketscreener.com/quote/stock/CLOVIS-ONCOLOGY-INC-9500801/news/Clovis-Oncology-s-Rubraca-Rucaparib-as-First-Line-Maintenance-Treatment-Improves-Progression-Free-41747647/